ZEUS A research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease chronic kidney disease and inflammation

Brief description of study

The purpose of this study is to see if the new study medicine, ziltivekimab, can be used to treat people with cardiovascular disease, chronic kidney disease and inflammation. The ZEUS study will see if ziltivekimab can reduce the risk of having cardiovascular events (for example heart attack and stroke). The term cardiovascular disease refers to several conditions that affect your heart and blood vessels. These conditions include myocardial infarction (also known as heart attack), stroke (also known as brain attack) and peripheral arterial disease (also known as poor circulation). Ziltivekimab is an antibody, which is designed to block the action of IL 6. In that way, ziltivekimab can help the body to avoid more inflammation.

Clinical Study Identifier: s22-00218
ClinicalTrials.gov Identifier: NCT05021835

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.